Global Reach With marketing authorisations in over 70 countries and a global footprint spanning R&D and manufacturing, ECO Animal Health presents opportunities to partner on international distribution, co-development, or regional licensing deals for pigs and poultry vaccines and antibiotics.

Late Pipeline A maturing proprietary R&D pipeline focused on late-stageMycoplasma vaccines for poultry and vaccines for swine signals potential for collaboration, licensing, or strategic investments to accelerate commercialization and expand product portfolio.

Lead Product Aivlosin® is a patented, proven antimicrobial effective against respiratory and intestinal diseases in pigs and poultry, indicating strong cross-market demand and opportunities for expansion through new formulations, enhanced stewardship programs, or regional promotions.

Recent Expansion EU poultry vaccine launch in 2026 and ongoing hiring of strategic Non-Executive Directors suggest a growth phase, creating openings for channel partnerships, co-marketing agreements, and tiered distribution strategies to scale presence in key markets.

Partnership Potential Active collaborations with research institutes (eg Moredun Group) and a global sales footprint imply fertile ground for joint research ventures, contract manufacturing, and customer-facing education programs to drive adoption and unlock new revenue streams.